# Frespaciguat PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/frespaciguat

> Frespaciguat, sponsored by Merck & Co., Inc. (MRK): 1 recorded catalyst.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | frespaciguat |
| Codes | MK-5475 |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | [Pulmonary Hypertension](https://sec-api.dev/indications/pulmonary-hypertension) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### April 9, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05612035 (Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-04-09 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT05612035

## Same indication

- [PF-07868489](https://sec-api.dev/pdufa/pf-07868489) (PFE)
- [WINREVAIR (sotatercept)](https://sec-api.dev/pdufa/sotatercept) (MRK)
- [TNX-103](https://sec-api.dev/pdufa/tnx-103) (TENX)
- [Treprostinil palmitil inhalation powder](https://sec-api.dev/pdufa/treprostinil-palmitil-inhalation-powder) (INSM)
- [Tx000045- dose a](https://sec-api.dev/pdufa/tx000045) (TECX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/frespaciguat.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Frespaciguat PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/frespaciguat

```bibtex
@misc{secapidev_pdufa_frespaciguat_20261116,
  title        = {Frespaciguat PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/frespaciguat}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_frespaciguat_20261116","title":"Frespaciguat PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/frespaciguat","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
